학술논문
Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas
Document Type
Article
Author
Source
In Clinical Lymphoma, Myeloma and Leukemia April 2023 23(4):259-265
Subject
Language
ISSN
2152-2650